Publications by authors named "Kou Masaki"
Background: Immune-checkpoint inhibitors (ICIs) are effective against various cancers; however, immune-related adverse events (irAEs) have been reported and the timing and risk factors are unknown. Therefore, we examined the incidence and timing of irAE occurrence.
Methods: Patients who received ICIs at our hospital between 1 April 2016 and 31 March 2020 were enrolled.